Recent public news coverage on Medicure Inc is limited and dated, with the most notable article from 2017 discussing the company as a value investment candidate.

• An article published on September 20, 2017, discusses Medicure Inc. as a potential value investment, highlighting its business and market position at that time [N1].
• The company filed a Form 20-F annual report on April 23, 2026, providing detailed disclosures on governance, financials, and risk factors [S1].
• A Form 6-K filing was submitted on April 22, 2026, including a press release and updates on company operations [S2].

Medicure’s established FDA-approved supply contracts and diversified business segments in product distribution and retail pharmacy provide a foundation for stable operations. The company’s moderate liquidity position and governance structure with an independent audit committee support operational oversight. Its revenue concentration among key customers may enable focused relationship management and potential for stable sales. The company’s adherence to IFRS and transparent financial reporting enhance visibility into its financial health.

Medicure faces risks from its dependence on third-party manufacturers for raw materials and finished products, with supply contracts subject to expiration and renewal risks. The high concentration of revenue among a few customers increases vulnerability to customer loss or changes in purchasing patterns. Regulatory compliance and reimbursement uncertainties in the pharmaceutical industry may adversely affect product commercialization and profitability. The company’s net losses and accumulated deficit indicate ongoing challenges in achieving sustained profitability. Limited recent public news coverage reduces external visibility into business developments.

Medicure’s moat is primarily based on its established supply contracts with FDA-approved manufacturers for key pharmaceutical products, which may provide some barriers to entry for competitors. The company’s focus on both commercial product distribution and retail/mail order pharmacy services allows it to serve multiple channels in the pharmaceutical supply chain. However, the company’s reliance on a limited number of customers and third-party suppliers introduces vulnerabilities. The regulatory approvals and compliance requirements for its products also create some barriers to entry. Overall, the moat is moderate, supported by regulatory and supply chain relationships but challenged by customer concentration and third-party dependencies.

• Supply Chain Dependency: Medicure relies on third-party manufacturers for raw materials and finished products, including FDA-approved suppliers. Disruptions or termination of these supply contracts could materially impact operations and financial results.
• Customer Concentration: A significant portion of revenue is derived from a small number of customers, increasing risk if any major customer reduces orders or terminates the relationship.
• Regulatory and Reimbursement Risks: The company’s products require regulatory approvals and are subject to government and insurance reimbursement policies, which may affect market access and profitability.
• Financial Performance: Medicure has reported net losses and an accumulated deficit, indicating challenges in achieving profitability and potential liquidity constraints.

• Medicure Inc is a Canadian company with operations primarily in the United States.
• The company operates two segments: marketing and distribution of commercial products, and retail and mail order pharmacy.
• 100% of revenue is generated from sales to customers in the United States.
• In 2025, seven customers accounted for all revenue in the marketing and distribution segment, with three customers accounting for the majority (Customer A 29%, Customer B 18%, Customer C 49%).
• Medicure's subsidiaries include Medicure International, Inc. and Medicure Pharma, Inc., which have FDA-approved supply contracts and manufacturing arrangements for products such as AGGRASTAT® and ZYPITAMAG®.
• The company relies on third-party manufacturers for raw materials and finished products, with supply contracts expiring in 2029 for ZYPITAMAG®.
• Revenue for Q1 2025 was CAD 5.484 million, with a net loss of CAD 0.694 million and basic and diluted EPS of -0.07 CAD per share.
• As of March 31, 2025, Medicure had cash and cash equivalents of CAD 7.216 million, current assets of CAD 15.782 million, current liabilities of CAD 9.236 million, resulting in a current ratio of 1.71 and a cash ratio of 0.78.
• The company’s Audit and Finance Committee is composed of four independent directors with financial literacy and experience relevant to the company’s financial reporting and controls.
• Medicure follows IFRS accounting standards and uses the Black-Scholes model for share-based payment valuation.
• The company’s financial statements show a net loss of CAD 7.097 million for the year ended December 31, 2025, with accumulated deficit of CAD 73.988 million as of that date.
• Medicure’s revenues are recognized at the point of delivery or payment depending on the sales channel, consistent with IFRS 15 revenue recognition principles.
• The company’s primary currency of operations is the Canadian dollar, with significant operations and revenues denominated in US dollars.
• Medicure’s business is subject to risks related to third-party manufacturing, regulatory approvals, reimbursement policies, and customer concentration.
• The company’s liquidity management focuses on maintaining sufficient cash and capital to fund operations and development activities.
• Recent news coverage is limited and dated, with a notable article from 2017 discussing the company as a value investment candidate.